Area of research
Oncology · Genetics
Research interest
Research interests include CAR-T cell therapy research, Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, and Acute Lymphoblastic Leukemia research.
Abstract 2003: Epigenetic And Phenotypic Modulation Of Adventitial Fibroblasts In Atherosclerosis By Coronary Artery Risk Gene Tcf21
Peripheral voltage-gated calcium channels in skin are essential for transient neurogenic thermal hyperalgesia in mice
Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia
Second Interim Analysis of a Phase 3 Study of Idelalisib (ZYDELIG®) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient Subpopulations with Del(17p) and Other Adverse Prognostic Factors
Final results of a phase I study of idelalisib (GSE1101) a selective inhibitor of PI3Kδ, in patients with relapsed or refractory CLL.
Use of tumor genomic profiling to reveal mechanisms of resistance to the BTK inhibitor ibrutinib in chronic lymphocytic leukemia (CLL).
Update on a phase I study of the selective PI3Kδ inhibitor idelalisib (GS-1101) in combination with rituximab and/or bendamustine in patients with relapsed or refractory CLL.